Dyne Therapeutics Reports Q1 Results, Confirms DMD BLA Submission on Track for Q2 2026, Extends Cash Runway

summarizeSummary

Dyne Therapeutics reported Q1 2026 financial results, including a net loss of $(120.9) million, while reaffirming its cash runway into Q1 2028 and providing positive updates on its lead clinical programs for DMD and DM1, including BLA submission timelines.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $(120.9) million, or $(0.73) per diluted share, for Q1 2026. R&D expenses decreased to $100.9 million, while G&A expenses increased to $24.4 million due to launch preparation.

• Cash Runway Extended

  Cash, cash equivalents, and marketable securities stood at $972.2 million as of March 31, 2026, sufficient to fund operations into Q1 2028.

• DMD Program (z-rostudirsen) on Track for BLA Submission

  Completed a positive pre-BLA meeting with the FDA and remains on track to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026, with a potential U.S. launch in Q1 2027. A global confirmatory Phase 3 trial will also initiate in Q2 2026.

• DM1 Program (z-basivarsen) Advances

  Reached the enrollment target of 60 participants in the ACHIEVE registrational expansion cohort, with data expected in Q1 2027 to support a potential BLA submission in early Q3 2027. The global confirmatory Phase 3 HARMONIA trial was initiated in March 2026.

auto_awesomeAnalysis

This filing is highly important as it provides a comprehensive update on Dyne Therapeutics' financial health and, more critically, its clinical pipeline. The confirmation of a positive pre-BLA meeting and the timeline for BLA submission for its Duchenne muscular dystrophy (DMD) program (z-rostudirsen) in Q2 2026, with a potential launch in Q1 2027, represents a significant de-risking event and a major step towards commercialization. Simultaneously, the DM1 program (z-basivarsen) is also advancing well, with enrollment targets met and a Phase 3 trial initiated. The extended cash runway into Q1 2028 provides financial stability to execute on these critical milestones.